Search Results

• 20231800-EMBOLIC

  EMPRO: Embolic Protection in Patients Undergoing High-Risk Valve Surgery

• 2023P000357

  Treat-to-Target Serum Urate versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial (TRUST trial)

• 21-101

  CONFORM: An Evaluation of the Safety and Effectiveness of the Conformal CLAAS System for Left Atrial Appendage Occlusion

• 2102248177

  Waterproof casting versus standard casting for short leg walking casts: a prospective randomized controlled trial

• 2103270150

  The Longitudinal Assessment of Physiological, Cognitive, and Behavioral Characteristics of Patients with Substance Use Disorders via Wearable Technologies and Ecological Momentary Assessment

• 22-001273

  Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

• 2201

  Re-Evaluation of the Corvia Atrial Shunt Device in a Precision Medicine Trial to Determine Efficacy in Mildly Reduced or Preserved EF Heart Failure

• 2201501642

  Evaluation of Wearable Technology for Chronic Stress and Burnout

• 2205578909

  Investigating human cognition with medically necessary intracranial electrophysiologic recordings

• 2206599818

  Pilot study to standardize visual cues and cognitive tasks for substance use disorder

• 2207618749

  Assessment of Thin-Film Microelectrode Arrays for Intraoperative Neurophysiology

• 2210661731

  Role of Wearable Devices and Data Analytics in Developing Tools for Early Diagnosis and Prognosis of Movement Disorders

• 2212689735

  WVU RNI Mind and Brain (MiBrain) Registry

• 23-001

  RCTof FlowTriever vs anticoagulation alone in pulmonary embolism

• 23-002

  RevCore for In Stent Thrombosis (REVIT)

• 2303735843

  The Utilization of Machine Learning Technologies in Predicting Relapse: Identifying Risk Factors and Implementing Intervention Before Drug Use Occurs

• 2304754574

  Development of diagnostic tests for concussion in virtual reality

• 2305778641

  Imaging studies in Dementia and Neurodegenerative Diseases

• 2305791111

  The Utilization of Wearable Technology and Ecological Momentary Assessment for Real-time Monitoring of Participants in Interventional Clinical Trials

• 2307822474

  Retrospective and prospective follow up study for patients who participated in interventional clinical trials for substance use disorders at RNI

• 2308834792

  The Feasibility of Wearables Technology in Understanding Memory Disorders

• 2310860024

  Feasibility of Wearable Technologies and Ecological Momentary Assessment for Patients with Episodic Migraine

• 2310864810

  Analysis of Physiological Response Data and Assessments in Understanding Binge Eating Disorder and/or Obesity

• 2318309

  RANDOMIZED TRIAL OF EUS-GUIDED CELIAC PLEXUS BLOCK VS. SHAM FOR PALLIATION OF PAIN IN CHRONIC PANCREATITIS (EPOCH TRIAL)

• 2404952584

  WVU Department of Orthopaedics Musculoskeletal Oncology Biobank

• 2404953520

  Outcomes of Distal Radius Fracture Fixation using Specialized Threaded Pins (Tpins)

• 2404969491

  Pilot study to standardize visual cues for eating disorders

• 2406990363

  Expanding and Promoting Alternative Care and Knowledge in Decision-Making: The Expand Study Improving Shred Decision Making and Access to Non-Dialytic Treatment for People with Kidney Disease

• 276453

  Talk With Me Baby: Leveraging Well-Child Care to Enhance the Early Home Language Environment of Rural and Underserved Children

• 68284528MMY4006

  Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

• A011801

  The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

• A012103

  OptimICE-pCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

• A041703

  A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for PH-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease

• A051901

  Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (NIVO-MR2) Induction followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

• A081801

  Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO

• A092105

  Randomized Phase 2 Study of Nivolumab and Ipilimumab with or without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy

• A151804

  Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

• AIRR-0010SIV

  A Multi-Center, Prospective Registry to Evaluate the Continued Safety and Effectiveness of Hand and Wrist Products

• ALXN1720-MG-301

  A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis Protocol Number: ALXN1720-MG-301 IND Number: 150823

• AMAG-FER-CKD-354

  A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney Disease (CKD)

• ARISEII

  Evaluation of the GORE® Ascending Stent Graft (ASG device) in the Treatment of Lesions of the Ascending Aorta

• ASPIRE

  Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

• BB2121-EAP-001

  Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

• BPR-PIP-003

  A multicenter, open-label, single-arm, multiple-dose study to evaluate the safety, pharmacokinetics, and efficacy of ceftobiprole medocaril in term and pre-term neonates and infants up to 3 months of age with late-onset sepsis

• C-00700

  A Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, Pivotal Study to Assess the Efficacy of Revita® Duodenal Mucosal Resurfacing (DMR) on Body Weight Maintenance in Participants with Obesity and Who Have Achieved at Least 15% Weight Loss on Tirzepatide Obesity Pharmacotherapy (REMAIN-1) SITE # 01-1026 West Virginia University

• C1071032

  A Phase 3, Open-Label Study of Elranatamab Monotherapy versus Elotuzumab, Pomalidomide, Dexamethasone (EPd) or Pomalidomide, Brotezomib, Dexamethasone 9PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed/Refractory Multiple Myeloma who Received Prior Anti-CD38 Directed Therapy

• C5041047

  A Multi-Center, Prospective, Non-Interventional Study of Real-World Effectiveness of Etrasimod in Patients with Ulcerative Colitis (ENDEAVOUR-UC)

• CA057-008

  A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

• CCTL019B2003I

  Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) in diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

• CLFT218-2401

  A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and safety of FT218 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-Label Safety Extension

• COG-AALL1621

  AALL1621 - A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

• COG-ACNS1833

  A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

• COG-AGCT1531

  A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

• COG-APEC14B1

  APEC14B1 - Project: EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study.

• COMB157GUS10

  AGNOS: An 18-month, Open-label, Multi-Center Phase IV Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes

• CONTEMP-ICD

  Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy in Contemporary Heart Failure Patients with a Low Risk for Arrhythmic Death (CONTEMP-ICD)

• CP-2021-05

  Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

• CR1393

  Prospective non-randomized post market study collecting clinical data on safety and effectiveness of the remede System

• CREST2

  Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2)

• CRYONEUROLYSIS-1336

  Evaluating the Role of Ultrasound-guided Genicular Nerve Cryoneurolysis in Regional Anesthesia for Total Knee Arthroplasty

• CTN-0100

  Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

• D00411092

  Evolut EXPAND TAVR II Pivotal Trial

• D3250C00024

  A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA)

• D8535C00001

  CAMBRIA2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

• D9481C00001

  An open-label study to assess safety and efficacy of SZC in pediatric patients with hyperkalaemia

• D9722C00001

  A Randomised, Open-Label, Phase III Study of AZD5305 Plus Camizestrant versus Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy for the First-Line Treatment of BRCA1, BRCA2, or PALB2-mutated Patients with Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

• DERM-STUDY

  Lipomas treated with subcutaneous injections of cooled sodium chloride: an exploratory study

• EA2192

  APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2, or PALB2 Mutation

• EAA173

  Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

• EAF223

  GABLE: Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial

• EAY191

  Molecular Analysis for Combination Therapy Choice (ComboMATCH)

• EAY191-A3

  A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancer

• EAY191-A6

  A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations

• EAY191-N4

  A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

• EAY191-N5

  A Randomized Trial of Neratinib, A Pan-ErbB Inhibitor, Alone or in Combination with Palbociclib, A CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors - A ComboMATCH Treatment Trial

• EFC17504

  A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis

• EPFL002

  Evaluating Subcortical Brain Structures in Response to Presence Hallucinations for Parkinson's Disease- EPFL

• EXCLUDER

  GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study

• F8394-201

  A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations

• FAST-REGISTRY

  Fast Registry Protocol: Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia

• FRACTYLHUB

  Fractyl Hub: A Prospective, Randomized, Double-Blind, Sham- Controlled, Multi-Center Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita System in Subjects with Type 2 Diabetes on Insulin Therapy

• GO43878

  A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma

• GO44145

  SKYGLO: A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Safety and Efficacy of Glofitimab (RO7082859) in Combination with Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma

• GOG-3043

  A Randomized Controlled Trial of Robotic versus Open Surgery for Cervical Cancer (ROCC trial)

• GRAIL-MA-001

  REFLECTION: Real World Evidence for Learnings in Early Cancer Detection, a Clinical Practice Learning Program for Galleri

• GS-US-528-6363

  PURPOSE 4/HPTN 103: A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs

• GS-US-595-6184

  A Randomized, Open-Label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

• HIE-RLS-0071

  A Phase 2, Two-Stage, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS0071 in Newborns with Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia with Long-Term Follow-Up (STAR)

• HIFLO

  Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care

• HLX10-005-SCLC301-E

  A Randomized, Open-label Study of HLX10 plus Chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Lung Cancer (ES-SCLC)

• HP-00111318

  Continuum of Care in Hospitalized Patients with Opioid Use Disorder (OUD) and Infectious Complications of Drug Use - NavSTAR, TAU, Addiction/ID Integrated Clinic to Prevent Infection Related Readmission (CHOICE-STAR)

• HZNP-TEP-305

  A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants with Moderate-to-Severe Active Thyroid Eye Disease

• IMVT-1401-3202

  IMVT-1401-3202: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease

• IMVT-1401-3203

  An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)

• INCA-34176-357

  A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

• INSIGHT018/ACTIV

  Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE)

• IPACK-3059

  Adductor Canal Block (ACB), Interspace Between the Popliteal Arterial and Capsule of the Knee (IPACK), and Anterior Femoral Cutaneous Nerve Peripheral Nerve Blocks Versus Mepivacaine Spinal for Total Knee Arthroplasty

• JCAR017-EAP-001

  Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

• KPI-012-C-001

  A Study to Evaluate the Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants with Persistent Corneal Epithelial Defect (PCED)

• KT-US-471-0140

  Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtegene Ciloleucel

• KT-US-472-0141

  Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication

• LUNGMAP

  A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

• M16-000

  A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991.

• M17-380

  A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children from 2 to Less than 12 Years of Age with Moderate to Severe Atopic Dermatitis (START UP)

• M19-973

  OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1)

• M22-418

  A Phase 3 Multicenter 24-Week Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine

• M23-714

  A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension [Protocol M23-714]

• MAGICAL

  The MAGICAL ISR Trial - A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Superiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus- Coated Balloon in the Treatment of Coronary In- Stent Restenosis

• MDT17074SD1706

  Prospective, Randomized, Controlled, Blinded Pivotal Study In Subjects Undergoing A Transforaminal Lumbar Interbody Fusion (TLIF) At One Or Two Levels Using Infuse Bone Graft and The Capstone Spinal System With Posterior Supplemental Fixation For The Treatment Of Symptomatic Degenerative Disease Of The Lumbosacral Spine

• MOTION

  The MOTION(TM) Study

• MTR2023-01

  A multi-center, early feasibility study of using the Mechanical Tissue Resuscitation (MTR) therapy system for removal of excess fluid in subjects who have had a portion of their skull removed to expose the dura/brain and require drainage for fluid removal.

• NCBP6637-01

  A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

• ND-OCT

  Evaluation of retinal imaging as a predictive marker in neurodegenerative diseases

• NRG-BR009

  A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score </= 25 (OFSET)

• NRG-CC005

  Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (FORTE)

• NRG-CC008

  A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROCk)

• NRG-GI008

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)

• NRG-GY019

  A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

• NRG-GY026

  A Phase III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) in HER2 Positive, Stage I-IV Endometrial Cancer

• NRG-LU008

  Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

• NSABP-B64

  EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease

• PICASSO

  Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

• PICU-UP

  Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children: A pragmatic, stepped-wedge trial

• PR2052

  Paclitaxel Coated balloon for the Treatment of chronic bEnigN sTricture-Esophagus (PATENT-E)

• PR2053

  Paclitaxel Coated balloon for the Treatment of chronic bEnigN sTricture-Bowel (PATENT-B)

• PRIMARY-CTSN

  Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for >65 Year-olds

• R3767-ONC-22122

  A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab In Participants with Unresectable or Metastatic Melanoma

• RECOVER-ENERGIZE

  RECOVER-ENERGIZE: A Platform Protocol for Evaluation of Interventions for Exercise Intolerance in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

• RECOVER-SLEEP

  RECOVER-SLEEP: A Platform Protocol for Evaluation of Interventions for Sleep Disturbances in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

• REMAIN-1-FRACTYL-HUB

  REMAIN-1-FRACTYL-HUB: A Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, Pivotal Study to Assess the Efficacy of Revita® Duodenal Mucosal Resurfacing (DMR) on Body Weight Maintenance in Participants with Obesity and Who Have Achieved at Least 15% Weight Loss on Tirzepatide Obesity Pharmacotherapy (REMAIN-1)

• REV1

  Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG

• RM-493-035

  SETMELANOTIDE RM-493-035 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway

• RPC-1063-MS-001

  A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063)

• RTOG1216

  Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

• S1501

  Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

• S1802

  Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

• S1827

  MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

• S1900J

  A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNGMAP Sub-Study)

• S1905

  A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / T-Cell Lymphoblastic Lymphoma (T-LBL)

• S2012

  Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

• S2212

  Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

• SATURN

  STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS

• SCOPE

  A 5-year Superion® IDS Clinical Outcomes Post-Approval Evaluation SCOPE

• SDAFF-2637

  Impact of Tai Chi on Balance in Patients with Cervical Myelopathy

• SLEEPSMART

  Sleep for Stroke Management And Recovery Trial

• SLT-THERAPY

  Clarifying The Optimal Application of SLT Therapy

• SNDX-5613-0708

  A Phase 1, Open-Label, Dose-escalation, and Dose-Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin1 (NPM1), and Nucleoporin 98 (NUP98) Genes

• SPYRALAFFIRM

  The SPYRAL AFFIRM Global Clinical Study of Renal Denervation With the Symplicity Spyral Renal Denervation System in Subjects With Uncontrolled Hypertension (SPYRAL AFFIRM)

• STOP360-IP-22

  Standardizing Treatments for Pulmonary Exacerbations: A platform for evaluating treatment decisions to improve outcomes (STOP360)

• TIGER-PAC

  Targeted Intra-arterial Gemcitabine vs Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer

• TOUR006-T01

  A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Study of TOUR006 in Participants with Thyroid Eye Disease

• TP-001-21

  Multicenter trial of Antibiotic eluting Graft for promoting new bone growth in/near Infected bone Cavities

• TREETOPAIM2

  TREETOP Retention Aim 2: Pain Self-Management and Patient-Oriented Dosing for Pain and Retention in Office-Based Addiction Treatement: a Randomized Trial

• ULTRA

  Real-World effectiveness of Evoke®closed-loop spinal cord stimulation (CL-SCS) therapy in chronic pain patients (ULTRA).

• VRDN-003-301

  A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with active thyroid eye disease (TED) Reveal 1

• VX20-121-104

  A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

• WVU010220

  Phase I/II Study of Neoadjuvant FOLFIRINOX in Combination with Peri-Operative Oral Hydroxychloroquine (FHQ) in Subjects with Resectable Adenocarcinoma of the Pancreas

• WVU010922

  Prospective Evaluation of Xerava (Eravacycline) Prophylaxis in Hematological Malignancy Patients with Prolonged Neutropenia

• WVU011115

  Skeletal Muscle Tissue Procurement for the Study of Breast Cancer -Associated Gene Expression

• WVU020220

  Safety and Feasibility of Prophylactic Heated Intra-peritoneal Chemotherapy (HIPEC) for High-Risk Gallbladder Adenocarcinoma

• WVU02HSC23

  A pilot study investigating the correlation between circulating cell-free mitochondria and fatigue in multiple sclerosis patients.

• WVU02HSC24

  WVU02HSC24: Development and Feasibility of Comprehensive Occupational Physical Activity Measurement for Cardiovascular Health - Phase 2

• WVU02HSC25

  Emergency Department Xylazine Testing to Improve Addiction Treatment

• WVU03HSC23

  Role of Cytb5R1 and Dcytb on oxidative stress in ulcerative colitis human colon

• WVU03HSC24

  Evaluating the gut microbiome from diagnosis through surveillance in colorectal cancer patients in Appalachia

• WVU04HSC23

  Change in Fructosamine before and one month after the bariatric surgery predict weight loss, six months after surgery.

• WVU04HSC24

  Limb Speed Perception Accuracy in Early Parkinson's Disease

• WVU04HSC25

  Comparison of Peer vs Family-Jiu-Jitsu for Individuals with Disabilities

• WVU05HSC25

  Improving Post-Hospitalization Outcomes for Rural Populations

• WVU06HSC24

  Optimizing the rTMS-concurrent behavioral priming for reducing smoking cravings

• WVU07HSC24

  Mobile minds: Evaluating Learning & Memory in Infants w/ Neonatal Abstinence Syndrome

• WVU08HSC18

  Development and Pilot Test of Internet-delivered Postpartum Anxiety Prevention

• WVU09HSC21

  Identification of Biomarkers for Inflammatory Bowel Disease

• WVU09HSC24

  Mucosal IgA antibodies against non-structural proteins in the protective immunity against SARS-CoV-2

• WVU13HSC20

  Effects of Blocking Blue Light at Night on Patient Outcomes after Elective CABG Surgery

• WVU13HSC21

  Evaluation of Group Obesity Therapy Implementation using Implementation Framework

• WVU15HSC21

  Protocol 1 Longitudinal Assessment of Immune Response Characterization and Correlates of Protection Among SARS CoV-2 Vaccine Recipients residing in Nursing Home or Assisted Living settings in West Virginia

• XPORT-MF-034

  A Phase 1 / Phase 3 Study to Evaluate the Efficacy and Safety of Selinexor, A Selective Inhibitor of Nuclear Export, in Combination with Ruxolitinib in Treatment-Naïve Patients with Myelofibrosis

Refine Search